Prognostic factors are important for treatment decisions as they help adapt the therapy on a case-to-case basis. Nodal status, number of positive nodes, and presence of extracapsular spread are considered to be the important prognostic factors in head and neck cancer. Some studies suggest that human papillomavirus (HPV) status also influences the outcome of the treatment. This influence can be explained by the variation in tendency to develop regional metastases and by variation in the type of neck node involvement. The study objectives were to compare patients with HPV positive and HPV-negative tumors for survival and prevalence and type of regional metastasis, to identify prognostic factors and to test whether HPV presence is an independent factor of survival. The study included 81 patients treated by surgery including neck dissection for oral or oropharyngeal squamous cell cancer. A computerized medical report was completed for each patient. Analysis of the tumor specimen for the HPV DNA presence was done on paraffin-fixed tissue. HPV DNA detection and typing were performed by PCR with GP5+/GP6+BIO primers and reverse line blot hybridization. Overall, 64% (52/81) of tumors were HPV positive with 80% in the tonsillar site. HPV-positive patients had significantly better both overall (73 vs. 35%) (P=0.0112) and disease-specific (79 vs. 45%) (P=0.0015) survival rates than HPV-negative patients. No significant differences were found in the pN classification, in the number of positive nodes and the presence of extracapsular spread in the involved nodes between HPV positive and HPV-negative tumors. Multivariate analysis showed that significant prognostic factors of survival were the presence of HPV in the tumor, extracapsular spread and tumor size. HPV was the most significant prognostic factor in the studied group of patients with oropharyngeal tumors (HR=0.27, 95%CI 0.12-0.61) and possibly should be considered in treatment decisions.

Department of Otolaryngology Head and Neck Surgery 1st Faculty of Medicine Charles University Prague Czech Republic

Zobrazit více v PubMed

Otolaryngol Head Neck Surg. 2001 Jul;125(1):1-9 PubMed

Clin Cancer Res. 2002 Apr;8(4):1093-100 PubMed

Int J Cancer. 2003 Nov 10;107(3):401-6 PubMed

Med Microbiol Immunol. 2003 Aug;192(3):129-32 PubMed

Clin Cancer Res. 2003 Jul;9(7):2620-6 PubMed

Int J Cancer. 2004 Feb 20;108(5):766-72 PubMed

Oral Dis. 2005 May;11(3):181-5 PubMed

J Clin Microbiol. 2002 Mar;40(3):779-87 PubMed

Adv Cancer Res. 2005;93:59-89 PubMed

Int J Cancer. 2000 May 20;89(3):300-4 PubMed

Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 PubMed

Int J Cancer. 2004 Dec 20;112(6):1015-9 PubMed

Clin Otolaryngol. 2006 Aug;31(4):259-66 PubMed

N Engl J Med. 2001 Apr 12;344(15):1125-31 PubMed

Cancer Res. 1998 Jan 1;58(1):5-13 PubMed

Cancer Lett. 2005 Feb 10;218(2):199-206 PubMed

Cancer. 2003 Mar 15;97(6):1464-70 PubMed

Head Neck. 2007 Aug;29(8):779-92 PubMed

J Natl Cancer Inst. 2000 May 3;92(9):709-20 PubMed

Int J Cancer. 2003 Apr 10;104(3):336-44 PubMed

Cancer. 2001 Aug 15;92(4):805-13 PubMed

Oncol Rep. 2005 Nov;14(5):1239-47 PubMed

Int J Cancer. 2003 Sep 10;106(4):553-8 PubMed

Distinct patterns of intratumoral immune cell infiltrates in patients with HPV-associated compared to non-virally induced head and neck squamous cell carcinoma

High level of Tregs is a positive prognostic marker in patients with HPV-positive oral and oropharyngeal squamous cell carcinomas

The role of high-risk human papillomavirus infection in oral and oropharyngeal squamous cell carcinoma in non-smoking and non-drinking patients: a clinicopathological and molecular study of 46 cases

Human papillomavirus in head and neck tumors: epidemiological, molecular and clinical aspects